Fustibal is a biotechnology startup focused on fostering affordable healthcare through simpler science. Our mission is to develop antibody-based nanomedicines for multi-targeted cancer therapy. Our oncology therapeutics functionalize the tumor-targeting capability of antibodies with the large drug payload and the prolonged circulation time of nanomedicines for synergistic therapeutic effects. Through data-based computational platforms and modular drug design, we repurpose and improve existing chemical and biological pharmaceuticals for efficacy, safety, and unmet medical needs. Combining our science and business expertise, we offer the commercial opportunity to bring to market innovative lifesaving medicines to recapture prevailing markets and to capture new ones.